All In Biotech

NDA 204042 · Janssen Pharms

Invokana

Canagliflozin · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Mar 29, 2013

Approved uses

8

Original approval plus efficacy supplements

Registered trials

156

25 Phase 3, 13 recruiting

FAERS reports

29,868

19,370 serious, 700 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 21, 2026.

INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day. INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). To reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ). Not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m 2 ( 1 ). Limitations of Use INVOKANA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . INVOKANA is not recommended for use to improve glycemic control in patients with type 2 diabetes...

Mechanism: SGLT2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RT G ), and thereby increases urinary glucose excretion (UGE). Canagliflozin increases the delivery of sodium to the distal tubule by blocking SGLT2-dependent glucose and sodium reabsorption. This is believed to increase tubuloglomerular feedback and reduce intraglomerular pressure.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • INVOKANA · CANAGLIFLOZIN 300MG · TABLET, ORAL · Prescription · TE AB
  • INVOKANA · CANAGLIFLOZIN 100MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Canagliflozin" as an intervention, any sponsor and status, largest first.

All 156 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diabetic ketoacidosis3,441
  • toe amputation2,196
  • osteomyelitis2,165
  • acute kidney injury2,008
  • fungal infection1,447
  • weight decreased1,349
  • blood glucose increased1,235
  • gangrene1,086
  • cellulitis1,036
  • nausea1,026
  • off label use1,021
  • urinary tract infection1,019

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20113
20123
2013246
2014984
20157,889
20164,292
20174,362
20184,643
20192,386
20201,465
2021824
2022811
2023690
2024502
2025477
2026291

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Invokana (Canagliflozin)

2024 spending

$272M

Beneficiaries

55,993

255,843 claims

Per beneficiary

$4,859

$18.58 per unit

View as table
YearSpending
2020$571,448,119
2021$456,386,878
2022$427,366,295
2023$357,419,494
2024$272,062,235

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 448 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.